Muckle-Wells syndrome

Muckle-Wells Syndrome (MWS) is encountered mainly in Europe. Its onset occurs during the first two decades of life. Triggers to inflammatory attacks other than exposure to cold include stress and exercise.

In addition to episodes of fever, rash, arthralgias, abdominal pain and conjunctivitis, MWS patients develop progressive sensi-neural sensorineural deafness. As many as 25% of them will be burdened with the nephropathy of amyloidosis.

Anakinra is the current choice of drug to control the inflammatory attacks. It may also play a role in protecting against amyloid deposition.